Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03665038 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 28
- Enrollment target
NCT03665038 is a Phase 3 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 28 participants.
The verdict
NCT03665038, a Phase 3 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
Interventions
- DRUG Brexanolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-09-07 |
| Est. Completion | 2021-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03665038
The ClinicalTrials.gov registry entry for NCT03665038 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brexanolone is the first listed.
NCT03665038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03665038 about?
NCT03665038 is a clinical study titled "A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)". This is a multi-center study evaluating the safety, tolerability, and pharmacokinetics of brexanolone in the treatment of adolescent female participants with postpartum depression (PPD).
What is the current status of trial NCT03665038?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 28 participants. The study started on 2018-09-07. Estimated completion is 2021-01-08.
What interventions are being tested in trial NCT03665038?
The interventions under investigation include: Brexanolone (DRUG).
Who is sponsoring clinical trial NCT03665038?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.